Drug Approval | May 15, 2026
Alembic Pharma receives USFDA tentative approval for Darolutamide tablets
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
We are building an AI-native operating system for pharma sales and distribution
Researchers reported that patients treated with the wearable system were discharged around five days earlier than those receiving standard hospital-based care
Subscribe To Our Newsletter & Stay Updated
